APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Human aFGF

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Recombinant Human aFGF Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 17392079038 January 2026194 pages

Choose your research edition.

Industry ResearchRecombinant Human aFGF Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Human aFGF Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Recombinant Human aFGF Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Human aFGF Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Human aFGF Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Recombinant Human aFGF market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Recombinant Human aFGF is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Human aFGF is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Human aFGF is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Recombinant Human aFGF is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Recombinant Human aFGF include Merck, MP Biomedicals, Proteintech, InVitria, Sino Biological, Reprokine, ACROBiosystems, Assay Genie and Cell Biologics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Human aFGF market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Human aFGF and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Human aFGF sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Human aFGF market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Human aFGF Segment by Company

Merck

MP Biomedicals

Proteintech

InVitria

Sino Biological

Reprokine

ACROBiosystems

Assay Genie

Cell Biologics

Sartorius AG

Yeasen

MedChemExpress

Abcam

Basic Pharma

Recombinant Human aFGF Segment by Type

Acidic

Alkaline

Recombinant Human aFGF Segment by Application

Biopharmaceuticals

Cell Culture & Regenerative Medicine

In Vitro Diagnostics

Others

Recombinant Human aFGF Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Human aFGF market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Human aFGF and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Human aFGF.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Human aFGF market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Recombinant Human aFGF manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Recombinant Human aFGF in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Recombinant Human aFGF in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Recombinant Human aFGF Industry Trends Table 2. Recombinant Human aFGF Industry Drivers Table 3. Recombinant Human aFGF Industry Opportunities and Challenges Table 4. Recombinant Human aFGF Industry Restraints Table 5. Global Recombinant Human aFGF Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Recombinant Human aFGF Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Recombinant Human aFGF Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Recombinant Human aFGF Sales Market Share by Manufacturers Table 9. Global Recombinant Human aFGF Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global Recombinant Human aFGF Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Recombinant Human aFGF Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Recombinant Human aFGF Manufacturers, Product Type & Application Table 13. Global Recombinant Human aFGF Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Human aFGF by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Acidic Table 17. Major Manufacturers of Alkaline Table 18. Global Recombinant Human aFGF Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Recombinant Human aFGF Sales by Type (2021-2026) & (k units) Table 20. Global Recombinant Human aFGF Sales by Type (2027-2032) & (k units) Table 21. Global Recombinant Human aFGF Sales Market Share by Type (2021-2026) Table 22. Global Recombinant Human aFGF Sales Market Share by Type (2027-2032) Table 23. Global Recombinant Human aFGF Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Recombinant Human aFGF Revenue by Type (2021-2026) & (k units) Table 25. Global Recombinant Human aFGF Revenue by Type (2027-2032) & (k units) Table 26. Global Recombinant Human aFGF Revenue Market Share by Type (2021-2026) Table 27. Global Recombinant Human aFGF Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Biopharmaceuticals Table 29. Major Manufacturers of Cell Culture & Regenerative Medicine Table 30. Major Manufacturers of In Vitro Diagnostics Table 31. Major Manufacturers of Others Table 32. Global Recombinant Human aFGF Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Recombinant Human aFGF Sales by Application (2021-2026) & (k units) Table 34. Global Recombinant Human aFGF Sales by Application (2027-2032) & (k units) Table 35. Global Recombinant Human aFGF Sales Market Share by Application (2021-2026) Table 36. Global Recombinant Human aFGF Sales Market Share by Application (2027-2032) Table 37. Global Recombinant Human aFGF Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Recombinant Human aFGF Revenue by Application (2021-2026) & (k units) Table 39. Global Recombinant Human aFGF Revenue by Application (2027-2032) & (k units) Table 40. Global Recombinant Human aFGF Revenue Market Share by Application (2021-2026) Table 41. Global Recombinant Human aFGF Revenue Market Share by Application (2027-2032) Table 42. Global Recombinant Human aFGF Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Recombinant Human aFGF Sales by Region (2021-2026) & (k units) Table 44. Global Recombinant Human aFGF Sales Market Share by Region (2021-2026) Table 45. Global Recombinant Human aFGF Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Recombinant Human aFGF Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Recombinant Human aFGF Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Recombinant Human aFGF Sales by Country (2021-2026) & (k units) Table 49. North America Recombinant Human aFGF Sales by Country (2027-2032) & (k units) Table 50. Europe Recombinant Human aFGF Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Recombinant Human aFGF Sales by Country (2021-2026) & (k units) Table 52. Europe Recombinant Human aFGF Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Recombinant Human aFGF Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Recombinant Human aFGF Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Recombinant Human aFGF Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Recombinant Human aFGF Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Recombinant Human aFGF Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Recombinant Human aFGF Sales by Country (2027-2032) & (k units) Table 59. Global Recombinant Human aFGF Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Recombinant Human aFGF Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Recombinant Human aFGF Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Recombinant Human aFGF Revenue Market Share by Region (2021-2026) Table 63. Global Recombinant Human aFGF Revenue Market Share by Region (2027-2032) Table 64. Merck Company Information Table 65. Merck Business Overview Table 66. Merck Recombinant Human aFGF Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Merck Recombinant Human aFGF Product Portfolio Table 68. Merck Recent Development Table 69. MP Biomedicals Company Information Table 70. MP Biomedicals Business Overview Table 71. MP Biomedicals Recombinant Human aFGF Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. MP Biomedicals Recombinant Human aFGF Product Portfolio Table 73. MP Biomedicals Recent Development Table 74. Proteintech Company Information Table 75. Proteintech Business Overview Table 76. Proteintech Recombinant Human aFGF Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Proteintech Recombinant Human aFGF Product Portfolio Table 78. Proteintech Recent Development Table 79. InVitria Company Information Table 80. InVitria Business Overview Table 81. InVitria Recombinant Human aFGF Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. InVitria Recombinant Human aFGF Product Portfolio Table 83. InVitria Recent Development Table 84. Sino Biological Company Information Table 85. Sino Biological Business Overview Table 86. Sino Biological Recombinant Human aFGF Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Sino Biological Recombinant Human aFGF Product Portfolio Table 88. Sino Biological Recent Development Table 89. Reprokine Company Information Table 90. Reprokine Business Overview Table 91. Reprokine Recombinant Human aFGF Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Reprokine Recombinant Human aFGF Product Portfolio Table 93. Reprokine Recent Development Table 94. ACROBiosystems Company Information Table 95. ACROBiosystems Business Overview Table 96. ACROBiosystems Recombinant Human aFGF Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. ACROBiosystems Recombinant Human aFGF Product Portfolio Table 98. ACROBiosystems Recent Development Table 99. Assay Genie Company Information Table 100. Assay Genie Business Overview Table 101. Assay Genie Recombinant Human aFGF Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Assay Genie Recombinant Human aFGF Product Portfolio Table 103. Assay Genie Recent Development Table 104. Cell Biologics Company Information Table 105. Cell Biologics Business Overview Table 106. Cell Biologics Recombinant Human aFGF Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Cell Biologics Recombinant Human aFGF Product Portfolio Table 108. Cell Biologics Recent Development Table 109. Sartorius AG Company Information Table 110. Sartorius AG Business Overview Table 111. Sartorius AG Recombinant Human aFGF Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Sartorius AG Recombinant Human aFGF Product Portfolio Table 113. Sartorius AG Recent Development Table 114. Yeasen Company Information Table 115. Yeasen Business Overview Table 116. Yeasen Recombinant Human aFGF Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Yeasen Recombinant Human aFGF Product Portfolio Table 118. Yeasen Recent Development Table 119. MedChemExpress Company Information Table 120. MedChemExpress Business Overview Table 121. MedChemExpress Recombinant Human aFGF Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. MedChemExpress Recombinant Human aFGF Product Portfolio Table 123. MedChemExpress Recent Development Table 124. Abcam Company Information Table 125. Abcam Business Overview Table 126. Abcam Recombinant Human aFGF Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Abcam Recombinant Human aFGF Product Portfolio Table 128. Abcam Recent Development Table 129. Basic Pharma Company Information Table 130. Basic Pharma Business Overview Table 131. Basic Pharma Recombinant Human aFGF Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Basic Pharma Recombinant Human aFGF Product Portfolio Table 133. Basic Pharma Recent Development Table 134. Key Raw Materials Table 135. Raw Materials Key Suppliers Table 136. Recombinant Human aFGF Distributors List Table 137. Recombinant Human aFGF Customers List Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Recombinant Human aFGF Product Image Figure 2. Global Recombinant Human aFGF Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Human aFGF Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant Human aFGF Sales (2021-2032) & (k units) Figure 5. Global Recombinant Human aFGF Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Recombinant Human aFGF Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Acidic Image Figure 9. Alkaline Image Figure 10. Global Recombinant Human aFGF Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Recombinant Human aFGF Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Recombinant Human aFGF Sales Market Share by Type (2021-2032) Figure 13. Global Recombinant Human aFGF Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Recombinant Human aFGF Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Recombinant Human aFGF Revenue Market Share by Type (2021-2032) Figure 16. Biopharmaceuticals Image Figure 17. Cell Culture & Regenerative Medicine Image Figure 18. In Vitro Diagnostics Image Figure 19. Others Image Figure 20. Global Recombinant Human aFGF Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Recombinant Human aFGF Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Recombinant Human aFGF Sales Market Share by Application (2021-2032) Figure 23. Global Recombinant Human aFGF Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Recombinant Human aFGF Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Recombinant Human aFGF Revenue Market Share by Application (2021-2032) Figure 26. North America Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Recombinant Human aFGF Sales Market Share by Country (2021-2032) Figure 28. U.S. Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Recombinant Human aFGF Sales Market Share by Country (2021-2032) Figure 33. Germany Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Recombinant Human aFGF Sales Market Share by Country (2021-2032) Figure 40. China Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Recombinant Human aFGF Sales Market Share by Country (2021-2032) Figure 48. Brazil Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Recombinant Human aFGF Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Recombinant Human aFGF Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Recombinant Human aFGF Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Recombinant Human aFGF Revenue (2021-2032) & (US$ Million) Figure 59. North America Recombinant Human aFGF Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Recombinant Human aFGF Revenue (2021-2032) & (US$ Million) Figure 61. Europe Recombinant Human aFGF Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Recombinant Human aFGF Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Recombinant Human aFGF Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Recombinant Human aFGF Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Recombinant Human aFGF Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Recombinant Human aFGF Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Recombinant Human aFGF Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Acidic
  • Alkaline
Applications
  • Biopharmaceuticals
  • Cell Culture & Regenerative Medicine
  • In Vitro Diagnostics
  • Others
Companies covered
  • Merck
  • MP Biomedicals
  • Proteintech
  • InVitria
  • Sino Biological
  • Reprokine
  • ACROBiosystems
  • Assay Genie
  • Cell Biologics
  • Sartorius AG
  • Yeasen
  • MedChemExpress
  • Abcam
  • Basic Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Recombinant Human aFGF Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Recombinant Human aFGF Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Recombinant Human aFGF Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Recombinant Human aFGF Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Recombinant Human aFGF Market Dynamics
  1. 2.1 Recombinant Human aFGF Industry Trends
  2. 2.2 Recombinant Human aFGF Industry Drivers
  3. 2.3 Recombinant Human aFGF Industry Opportunities and Challenges
  4. 2.4 Recombinant Human aFGF Industry Restraints
3 Recombinant Human aFGF Market by Manufacturers
  1. 3.1 Global Recombinant Human aFGF Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Recombinant Human aFGF Sales by Manufacturers (2021-2026)
  3. 3.3 Global Recombinant Human aFGF Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Recombinant Human aFGF Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Recombinant Human aFGF Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Recombinant Human aFGF Manufacturers, Product Type & Application
  7. 3.7 Global Recombinant Human aFGF Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Recombinant Human aFGF Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Recombinant Human aFGF Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Recombinant Human aFGF Tier 1, Tier 2, and Tier 3
4 Recombinant Human aFGF Market by Type
  1. 4.1 Recombinant Human aFGF Type Introduction
  2. 4.1.1 Acidic
  3. 4.1.2 Alkaline
  4. 4.2 Global Recombinant Human aFGF Sales by Type
  5. 4.2.1 Global Recombinant Human aFGF Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Recombinant Human aFGF Sales by Type (2021-2032)
  7. 4.2.3 Global Recombinant Human aFGF Sales Market Share by Type (2021-2032)
  8. 4.3 Global Recombinant Human aFGF Revenue by Type
  9. 4.3.1 Global Recombinant Human aFGF Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Recombinant Human aFGF Revenue by Type (2021-2032)
  11. 4.3.3 Global Recombinant Human aFGF Revenue Market Share by Type (2021-2032)
5 Recombinant Human aFGF Market by Application
  1. 5.1 Recombinant Human aFGF Application Introduction
  2. 5.1.1 Biopharmaceuticals
  3. 5.1.2 Cell Culture & Regenerative Medicine
  4. 5.1.3 In Vitro Diagnostics
  5. 5.1.4 Others
  6. 5.2 Global Recombinant Human aFGF Sales by Application
  7. 5.2.1 Global Recombinant Human aFGF Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Recombinant Human aFGF Sales by Application (2021-2032)
  9. 5.2.3 Global Recombinant Human aFGF Sales Market Share by Application (2021-2032)
  10. 5.3 Global Recombinant Human aFGF Revenue by Application
  11. 5.3.1 Global Recombinant Human aFGF Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Recombinant Human aFGF Revenue by Application (2021-2032)
  13. 5.3.3 Global Recombinant Human aFGF Revenue Market Share by Application (2021-2032)
6 Global Recombinant Human aFGF Sales by Region
  1. 6.1 Global Recombinant Human aFGF Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Human aFGF Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Human aFGF Sales by Region (2021-2026)
  4. 6.2.2 Global Recombinant Human aFGF Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Recombinant Human aFGF Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Recombinant Human aFGF Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Recombinant Human aFGF Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Recombinant Human aFGF Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Recombinant Human aFGF Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Recombinant Human aFGF Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Recombinant Human aFGF Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Recombinant Human aFGF Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Recombinant Human aFGF Revenue by Region
  1. 7.1 Global Recombinant Human aFGF Revenue by Region
  2. 7.1.1 Global Recombinant Human aFGF Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Recombinant Human aFGF Revenue by Region (2021-2026)
  4. 7.1.3 Global Recombinant Human aFGF Revenue by Region (2027-2032)
  5. 7.1.4 Global Recombinant Human aFGF Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Recombinant Human aFGF Revenue (2021-2032)
  8. 7.2.2 North America Recombinant Human aFGF Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Recombinant Human aFGF Revenue (2021-2032)
  11. 7.3.2 Europe Recombinant Human aFGF Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Recombinant Human aFGF Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Recombinant Human aFGF Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Recombinant Human aFGF Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Recombinant Human aFGF Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck Recombinant Human aFGF Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck Recombinant Human aFGF Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 MP Biomedicals
  8. 8.2.1 MP Biomedicals Company Information
  9. 8.2.2 MP Biomedicals Business Overview
  10. 8.2.3 MP Biomedicals Recombinant Human aFGF Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 MP Biomedicals Recombinant Human aFGF Product Portfolio
  12. 8.2.5 MP Biomedicals Recent Developments
  13. 8.3 Proteintech
  14. 8.3.1 Proteintech Company Information
  15. 8.3.2 Proteintech Business Overview
  16. 8.3.3 Proteintech Recombinant Human aFGF Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Proteintech Recombinant Human aFGF Product Portfolio
  18. 8.3.5 Proteintech Recent Developments
  19. 8.4 InVitria
  20. 8.4.1 InVitria Company Information
  21. 8.4.2 InVitria Business Overview
  22. 8.4.3 InVitria Recombinant Human aFGF Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 InVitria Recombinant Human aFGF Product Portfolio
  24. 8.4.5 InVitria Recent Developments
  25. 8.5 Sino Biological
  26. 8.5.1 Sino Biological Company Information
  27. 8.5.2 Sino Biological Business Overview
  28. 8.5.3 Sino Biological Recombinant Human aFGF Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sino Biological Recombinant Human aFGF Product Portfolio
  30. 8.5.5 Sino Biological Recent Developments
  31. 8.6 Reprokine
  32. 8.6.1 Reprokine Company Information
  33. 8.6.2 Reprokine Business Overview
  34. 8.6.3 Reprokine Recombinant Human aFGF Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Reprokine Recombinant Human aFGF Product Portfolio
  36. 8.6.5 Reprokine Recent Developments
  37. 8.7 ACROBiosystems
  38. 8.7.1 ACROBiosystems Company Information
  39. 8.7.2 ACROBiosystems Business Overview
  40. 8.7.3 ACROBiosystems Recombinant Human aFGF Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 ACROBiosystems Recombinant Human aFGF Product Portfolio
  42. 8.7.5 ACROBiosystems Recent Developments
  43. 8.8 Assay Genie
  44. 8.8.1 Assay Genie Company Information
  45. 8.8.2 Assay Genie Business Overview
  46. 8.8.3 Assay Genie Recombinant Human aFGF Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Assay Genie Recombinant Human aFGF Product Portfolio
  48. 8.8.5 Assay Genie Recent Developments
  49. 8.9 Cell Biologics
  50. 8.9.1 Cell Biologics Company Information
  51. 8.9.2 Cell Biologics Business Overview
  52. 8.9.3 Cell Biologics Recombinant Human aFGF Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cell Biologics Recombinant Human aFGF Product Portfolio
  54. 8.9.5 Cell Biologics Recent Developments
  55. 8.10 Sartorius AG
  56. 8.10.1 Sartorius AG Company Information
  57. 8.10.2 Sartorius AG Business Overview
  58. 8.10.3 Sartorius AG Recombinant Human aFGF Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sartorius AG Recombinant Human aFGF Product Portfolio
  60. 8.10.5 Sartorius AG Recent Developments
  61. 8.11 Yeasen
  62. 8.11.1 Yeasen Company Information
  63. 8.11.2 Yeasen Business Overview
  64. 8.11.3 Yeasen Recombinant Human aFGF Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Yeasen Recombinant Human aFGF Product Portfolio
  66. 8.11.5 Yeasen Recent Developments
  67. 8.12 MedChemExpress
  68. 8.12.1 MedChemExpress Company Information
  69. 8.12.2 MedChemExpress Business Overview
  70. 8.12.3 MedChemExpress Recombinant Human aFGF Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 MedChemExpress Recombinant Human aFGF Product Portfolio
  72. 8.12.5 MedChemExpress Recent Developments
  73. 8.13 Abcam
  74. 8.13.1 Abcam Company Information
  75. 8.13.2 Abcam Business Overview
  76. 8.13.3 Abcam Recombinant Human aFGF Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Abcam Recombinant Human aFGF Product Portfolio
  78. 8.13.5 Abcam Recent Developments
  79. 8.14 Basic Pharma
  80. 8.14.1 Basic Pharma Company Information
  81. 8.14.2 Basic Pharma Business Overview
  82. 8.14.3 Basic Pharma Recombinant Human aFGF Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Basic Pharma Recombinant Human aFGF Product Portfolio
  84. 8.14.5 Basic Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Human aFGF Value Chain Analysis
  2. 9.1.1 Recombinant Human aFGF Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Human aFGF Production Mode & Process
  6. 9.2 Recombinant Human aFGF Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Human aFGF Distributors
  9. 9.2.3 Recombinant Human aFGF Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst